251 results on '"Hanks, Brent A."'
Search Results
2. The State of Melanoma: Emergent Challenges and Opportunities
3. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma
4. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression
5. Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy
6. Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice
7. The utility of initial staging PET-CT as a baseline scan for surveillance imaging in stage II and III melanoma
8. Dissecting the immune landscape of tumor draining lymph nodes in melanoma with high-plex spatially resolved protein detection
9. Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma
10. 1254 Tumor-mediated education of bone marrow neutrophil progenitors facilitates the development of checkpoint inhibitor-associated toxicity
11. 747 Phase 1 trial of LYL845, an autologous tumor-infiltrating lymphocyte (TIL) therapy enhanced with epigenetic reprogramming, for the treatment of advanced solid tumors
12. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets
13. A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti-PD-1 immunotherapy
14. Retrospective analysis of safety and efficacy of anti-PD-1 therapy and radiation therapy in advanced melanoma: A bi-institutional study
15. Assessing the utility of molecular diagnostic classification for cancers of unknown primary
16. Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma
17. A SREBF2-dependent gene program drives an immunotolerant dendritic cell population during cancer progression
18. Supplementary Table S2 from APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses
19. Data from APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses
20. Supplementary Data Legends from APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses
21. Figures S1-S11 from APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses
22. Supplementary Figure S7 from Stromal Fibroblasts Mediate Anti–PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma
23. Supplementary Figures 1 - 18, Table 1 from Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
24. Data from Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy
25. Supplementary Table 1 from Stromal Fibroblasts Mediate Anti–PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma
26. Data from Stromal Fibroblasts Mediate Anti–PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma
27. Figure S1 from Ipilimumab and Radiation in Patients with High-risk Resected or Regionally Advanced Melanoma
28. Supplementary Methods from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
29. Data from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
30. Supplementary Figures 1-8 from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
31. The Enduring Effects of COVID for Cancer Care: Learning from Real-Life Clinical Practice
32. Safety and Efficacy of Radiation Therapy in Advanced Melanoma Patients Treated With Ipilimumab
33. Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma
34. Editorial: Signaling pathways behind immune evasion and therapy resistance
35. Tumor-intrinsic NLRP3-HSP70-TLR4 axis drives premetastatic niche development and hyperprogression during anti–PD-1 immunotherapy
36. 533 A tumor-lung NLRP3-TLR4 distant signaling axis drives immunotherapy resistance via G-CSF-dependent expansion of circulating PD1+PMN-MDSCs
37. 513 Overcoming hedgehog mediated anti-PD-1 resistance in melanoma through prostaglandin inhibition
38. 827 The role of combination immune checkpoint inhibitors as salvage therapy for PD-1/PD-L1-resistant merkel cell carcinoma
39. 22 Activity of the tumor-intrinsic NLRP3 inflammasome pathway predicts for response to checkpoint inhibitor immunotherapy in melanoma patients
40. Multicenter Experience with Neoadjuvant Therapy in Melanoma Highlights Heterogeneity in Contemporary Practice
41. Isolated recto-sigmoid colitis: a new imaging pattern of ipilimumab-associated colitis
42. The “Inside” Story on Tumor-Expressed PD-L1
43. Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events
44. Improved Time to Progression for Transarterial Chemoembolization Compared With Transarterial Embolization for Patients With Unresectable Hepatocellular Carcinoma
45. Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization
46. APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell–Mediated Antitumor Immune Responses
47. 319 The tumor-intrinsic NLRP3 inflammasome establishes a pulmonary metastatic niche via type II epithelial HSP70/TLR4 signaling and facilitates disease hyperprogression in response to immunotherapy
48. 923 Hedgehog signaling drives epithelial-to-mesenchymal transition, immune evasion, and anti-PD-1 resistance through coordinated upregulation of Wnt ligands and PGE2 synthesis
49. Complete Pathologic Response Predicts Disease-Free Survival for Melanoma Patients Undergoing Neoadjuvant Therapy
50. 657 Characterization and therapeutic targeting of a tumor-associated tolerogenic DC subpopulation driven by SREBP2 and the mevalonate metabolic pathway
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.